Strategic management paper for Boehriger Ingelheim Philippines

• Main Author: Guilas, Cecille Legados
• Format: text
• Language: English
• Published: Animo Repository 2006
• Subjects: Pharmaceutical industry > Philippines; Veterinary drug industry > Philippines; Boehriger Ingelheim Philippines
• Online Access: https://animorepository.dlsu.edu.ph/etd_masteral/3644
• Institution: De La Salle University

Boehringer Ingelheim Philippines is a wholly-owned subsidiary of Boehringer Ingelheim International GmBH, with headquarters in the city of Ingelheim am Rhein, Germany. Boehringer Ingelheim Philippines belongs to the Australasia section Boehringer Ingelheim Phil, Inc. (BIPHI) is one of the leading pharmaceutical companies in the Philippines. It markets human and animal health products (prescription medicines, consumer health products and animal vaccines) that are known for their quality and efficacy. The human pharmaceuticals business accounts for 95 percent (70.2% Prescription Medicines and 24.8% CHC) of the company's total revenue while the animal health division accounts for only 5%. The product line of Boehringer Ingelheim, (Phil.) Inc. is composed of cardiovascular, respiratory and neurological medicines. Boehringer Ingelheim, Phils. is divided into three divisions the Prescription Medicines Division, Consumer Health Care Division and the Animal Health Division. The Consumer Health Care Division markets OTC (over-the-counter) drugs such as Pharmaton, Dulcolax, Kiddi Pharmaton, and Bisolvon. The Prescription Medicines Division (Ethical) presently markets drugs such as Mucosolvan, Spiriva, Micardis, Micardis Plus, Sifrol, Mobic, Primavent, Persantin, Berodual, Combivent UDV, Aggrenox and Buscopan. The Animal Health Division markets animal vaccines such as Ingelvac, Enterisol, Reprocycle, Volvac and Bar Somnus.